Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oracea in Rosacea
NCT00126399Phase 3Completed
- Sponsor
- CollaGenex Pharmaceuticals
- Start
- Jun 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in rosacea comparing Oracea with Placebo (2 arms). Primary endpoint: Change in total inflammatory lesion count at 16 weeks. Started Jun 2004; status: completed.
02
Drugs
oracea
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT00126399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126399.